A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

  • STATUS
    Recruiting
  • days left to enroll
    63
  • participants needed
    618
  • sponsor
    Endo Pharmaceuticals
Updated on 28 May 2022
androgens
replacement therapy
testosterone
testosterone level
serum testosterone
hypogonadism
diastolic blood pressure
testosterone gel
hypogonadotropic hypogonadism
klinefelter syndrome
secondary hypogonadism
testim
screening procedure
aveed injectable product
fortesta

Summary

Testosterone is the principal androgen produced by the male testes. Hypogonadism is the result of inadequate production of testosterone by the Leydig cells of the testes and is reflected by total serum concentrations of testosterone of < 300 nanograms (ng)/deciliters (dL), with discernible diurnal pattern. The etiology of hypogonadism may be primary or secondary. The treatment of males with primary, and in some cases, secondary hypogonadism includes administration of testosterone.

Testim® and Fortesta® are topical gels that when applied daily help to increase the total testosterone levels in the blood through skin absorption. Aveed® is an injectable form of testosterone treatment and participants randomized to this treatment arm will receive 3 injections over the course of 16 weeks.

This study is designed to evaluate the effect on blood pressure of approved testosterone products (Testim®, Fortesta®, and Aveed®) after 16 weeks of therapy using 24-hour ambulatory blood pressure to reveal shifts in blood pressure levels.

Details
Condition Hypogonadism, Hypogonadism, Male, Hypogonadotropic Hypogonadism
Treatment Aveed Injectable Product, Fortesta or Testim, Aveed Injectable Product, Fortesta, Testim
Clinical Study IdentifierNCT04456296
SponsorEndo Pharmaceuticals
Last Modified on28 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Have a total serum testosterone at screening < 300 ng/dL based on 2 blood samples obtained at 10 am (+/-2 hours) on 2 separate occasions at least 48 hours apart
Be naïve to androgen replacement or washout of 12 weeks following intramuscular androgen injections; 4 weeks following topical or buccal, nasal, or oral androgens
Have a screening blood pressure at rest of less than 140 millimeters of mercury (mm Hg) for systolic blood pressure and less than 90 mm Hg for diastolic blood pressure
Be judged to be in good health
Participants enrolled in the Testim or Fortesta treatment arms: take necessary precautions to avoid skin-to-skin contact and potential transfer and if male use effective contraception
Be willing and able to cooperate with the requirements of the study

Exclusion Criteria

Is from a vulnerable population, as defined by the US Code of Federal Regulations (CFR) Title 45, Part 46, Section 46.111(b) and other local and national regulations, including but not limited to, employees (temporary, part-time, full time, etc) or a family member of the research staff conducting the study, or of the sponsor, or of the contract research organization, or of the Institutional Review Board/Independent Ethics Committee (IRB/IEC)
Has a history of significant sensitivity or allergy to the study drugs, including androgens, or product excipients
Has a history of or medical examination findings renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric conditions, cardiovascular disease/dysrhythmia) or any other condition(s) that restricts study participation
Has clinically significant changes in any medications (including dosages) or medical conditions in the 28 days prior to screening
Is not on a stable medication regimen for at least 3 months for the treatment of a chronic condition
Has had a cardiovascular and/or cerebrovascular event within the last 6 months
Needs blood pressure cuff size larger than 50 centimeters
Works a night shift or performs heavy manual labor
Has any known contraindication(s) to active study treatment including, but not limited to: known or suspected carcinoma of the prostate or breast, previous history of cancer (except basal cell carcinoma of the skin) liver disease, active deep vein thrombosis, atrial fibrillation, untreated sleep apnea, or is immune compromised
Uses any of the above listed drugs within 5 half lives of the last dose in the past 6 months prior to study drug administration
Uses known inhibitors (for example, ketoconazole) or inducers of cytochrome P450 3A (for example, dexamethasone, phenytoin, rifampin, carbamazepine) of cytochrome P450 3A (CYP3A) within 30 days prior to study drug administration and through the end of the study
Has received any of the above listed drugs by injection within 30 days or 10 half lives (whichever is longer) prior to study drug administration
Uses nutraceuticals or homeopathic compounds
Has untreated moderate to severe depression
Has a history of drug or alcohol abuse within 6 months prior to study drug
Has any skin lesions/cuts/injury at the application site
administration
Has suspected reversible hypogonadism
Donated blood or blood products or experienced significant blood loss within 90 days prior to study drug administration
Intends to conceive at any time during the study
Donated bone marrow within 6 months prior to study drug administration
Has participated in a previous investigational study or received treatment with an investigational product within 30 days of screening
Has a diagnosis of, is undergoing therapy for, or has received therapy for a hematologic malignancy in the 5 years prior to screening
Has a history of substance abuse or is taking any substance of abuse (Note: participants on a stable dose of any medications that have been prescribed by a healthcare practitioner for a properly documented medical condition are exempt)
Has evidence of abnormalities on physical examination, vital signs, ECG, or clinical lab values, unless judged to be clinically insignificant by the investigator
Abnormal electrocardiogram (ECG) (QT prolongation with QTc ≥450 milliseconds)
Has any other condition that might indicate the participant to be unsuitable for the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note